Mealey's (November 14, 2019, 1:04 PM EST) -- ALEXANDRIA, Va. — In a Nov. 11 petitioner reply filed with the Patent Trial and Appeal Board, a petitioner for post-grant review (PGR) of a cancer treatment patent maintains its position that the claimed technology suffers from a lack of enablement (Genome & Company v. University of Chicago, No. PGR2019-00002, PTAB)....